vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and Vital Farms, Inc. (VITL). Click either name above to swap in a different company.
Vital Farms, Inc. is the larger business by last-quarter revenue ($213.6M vs $168.4M, roughly 1.3× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 28.7%). Over the past eight quarters, Vital Farms, Inc.'s revenue compounded faster (20.2% CAGR vs 10.6%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Vital Tomosi Dairy Limited is a dairy processing company in Uganda. The company is a joint venture between Vital Capital Fund, "an impact investing fund primarily focused on Sub-Saharan Africa", and "Tomosi Dairy Farms, a Ugandan producer of dairy products".
ESPR vs VITL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $213.6M |
| Net Profit | — | $16.3M |
| Gross Margin | — | 35.8% |
| Operating Margin | 50.6% | 10.0% |
| Net Margin | — | 7.6% |
| Revenue YoY | 143.7% | 28.7% |
| Net Profit YoY | — | 54.3% |
| EPS (diluted) | $0.32 | $0.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $213.6M | ||
| Q3 25 | $87.3M | $198.9M | ||
| Q2 25 | $82.4M | $184.8M | ||
| Q1 25 | $65.0M | $162.2M | ||
| Q4 24 | $69.1M | $166.0M | ||
| Q3 24 | $51.6M | $145.0M | ||
| Q2 24 | $73.8M | $147.4M | ||
| Q1 24 | $137.7M | $147.9M |
| Q4 25 | — | $16.3M | ||
| Q3 25 | $-31.3M | $16.4M | ||
| Q2 25 | $-12.7M | $16.6M | ||
| Q1 25 | $-40.5M | $16.9M | ||
| Q4 24 | — | $10.6M | ||
| Q3 24 | $-29.5M | $7.4M | ||
| Q2 24 | $-61.9M | $16.3M | ||
| Q1 24 | $61.0M | $19.0M |
| Q4 25 | — | 35.8% | ||
| Q3 25 | — | 37.7% | ||
| Q2 25 | — | 38.9% | ||
| Q1 25 | — | 38.5% | ||
| Q4 24 | — | 36.1% | ||
| Q3 24 | — | 36.9% | ||
| Q2 24 | — | 39.1% | ||
| Q1 24 | — | 39.8% |
| Q4 25 | 50.6% | 10.0% | ||
| Q3 25 | -11.4% | 10.8% | ||
| Q2 25 | 8.6% | 12.9% | ||
| Q1 25 | -34.0% | 13.4% | ||
| Q4 24 | -6.4% | 7.8% | ||
| Q3 24 | -31.0% | 6.4% | ||
| Q2 24 | 3.5% | 11.6% | ||
| Q1 24 | 52.5% | 16.3% |
| Q4 25 | — | 7.6% | ||
| Q3 25 | -35.9% | 8.3% | ||
| Q2 25 | -15.4% | 9.0% | ||
| Q1 25 | -62.2% | 10.4% | ||
| Q4 24 | — | 6.4% | ||
| Q3 24 | -57.2% | 5.1% | ||
| Q2 24 | -83.9% | 11.1% | ||
| Q1 24 | 44.3% | 12.9% |
| Q4 25 | $0.32 | $0.35 | ||
| Q3 25 | $-0.16 | $0.36 | ||
| Q2 25 | $-0.06 | $0.36 | ||
| Q1 25 | $-0.21 | $0.37 | ||
| Q4 24 | $-0.14 | $0.23 | ||
| Q3 24 | $-0.15 | $0.16 | ||
| Q2 24 | $-0.33 | $0.36 | ||
| Q1 24 | $0.34 | $0.43 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $48.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $351.3M |
| Total Assets | $465.9M | $518.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $48.8M | ||
| Q3 25 | $92.4M | $93.8M | ||
| Q2 25 | $86.1M | $108.2M | ||
| Q1 25 | $114.6M | $156.3M | ||
| Q4 24 | $144.8M | $150.6M | ||
| Q3 24 | $144.7M | $149.5M | ||
| Q2 24 | $189.3M | $133.2M | ||
| Q1 24 | $226.6M | $113.8M |
| Q4 25 | $-302.0M | $351.3M | ||
| Q3 25 | $-451.4M | $331.2M | ||
| Q2 25 | $-433.5M | $309.8M | ||
| Q1 25 | $-426.2M | $288.9M | ||
| Q4 24 | $-388.7M | $269.3M | ||
| Q3 24 | $-370.2M | $253.4M | ||
| Q2 24 | $-344.2M | $238.4M | ||
| Q1 24 | $-294.3M | $213.3M |
| Q4 25 | $465.9M | $518.7M | ||
| Q3 25 | $364.0M | $481.5M | ||
| Q2 25 | $347.1M | $430.8M | ||
| Q1 25 | $324.0M | $376.9M | ||
| Q4 24 | $343.8M | $359.3M | ||
| Q3 24 | $314.1M | $344.7M | ||
| Q2 24 | $352.3M | $320.5M | ||
| Q1 24 | $373.1M | $300.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $5.8M |
| Free Cash FlowOCF − Capex | — | $-32.1M |
| FCF MarginFCF / Revenue | — | -15.1% |
| Capex IntensityCapex / Revenue | 0.0% | 17.8% |
| Cash ConversionOCF / Net Profit | — | 0.35× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-48.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $5.8M | ||
| Q3 25 | $-4.3M | $23.4M | ||
| Q2 25 | $-31.4M | $-761.0K | ||
| Q1 25 | $-22.6M | $5.3M | ||
| Q4 24 | $-35.0M | $14.8M | ||
| Q3 24 | $-35.3M | $10.0M | ||
| Q2 24 | $-7.2M | $16.1M | ||
| Q1 24 | $53.8M | $23.9M |
| Q4 25 | — | $-32.1M | ||
| Q3 25 | — | $-10.6M | ||
| Q2 25 | — | $-7.6M | ||
| Q1 25 | — | $2.1M | ||
| Q4 24 | — | $-3.4M | ||
| Q3 24 | $-35.5M | $6.4M | ||
| Q2 24 | $-7.3M | $10.5M | ||
| Q1 24 | $53.8M | $22.6M |
| Q4 25 | — | -15.1% | ||
| Q3 25 | — | -5.3% | ||
| Q2 25 | — | -4.1% | ||
| Q1 25 | — | 1.3% | ||
| Q4 24 | — | -2.0% | ||
| Q3 24 | -68.7% | 4.4% | ||
| Q2 24 | -9.9% | 7.2% | ||
| Q1 24 | 39.0% | 15.3% |
| Q4 25 | 0.0% | 17.8% | ||
| Q3 25 | 0.0% | 17.1% | ||
| Q2 25 | 0.0% | 3.7% | ||
| Q1 25 | 0.0% | 1.9% | ||
| Q4 24 | 0.0% | 10.9% | ||
| Q3 24 | 0.3% | 2.5% | ||
| Q2 24 | 0.1% | 3.8% | ||
| Q1 24 | 0.1% | 0.9% |
| Q4 25 | — | 0.35× | ||
| Q3 25 | — | 1.43× | ||
| Q2 25 | — | -0.05× | ||
| Q1 25 | — | 0.31× | ||
| Q4 24 | — | 1.40× | ||
| Q3 24 | — | 1.34× | ||
| Q2 24 | — | 0.99× | ||
| Q1 24 | 0.88× | 1.26× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
VITL
| Eggs And Egg Related Products | $205.8M | 96% |
| Butter And Butter Related Products | $7.7M | 4% |
